Structural basis for simvastatin-induced skeletal muscle weakness associated with type 1 ryanodine receptor T4709M mutation
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci194490 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Gunnar Weninger und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Cellular Biophysics, Clyde and Helen Wu Center for Molecular Cardiology, Vagelos College of Physicians and Surgeons, Col…. Hauptthemen laut MEDLINE: Ryanodine Receptor Calcium Release Channel, Simvastatin, Muscle Weakness, Muscle, Skeletal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NHLBI NIH HHS, National Institutes of Health / National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Statins lower cholesterol, reducing the risk of heart disease, and are among the most frequently prescribed drugs. Approximately 10% of individuals develop statin-associated muscle symptoms (SAMS; myalgias, rhabdomyolysis, and muscle weakness), often rendering them statin intolerant. The mechanism underlying SAMS remains poorly understood. Patients with mutations in the skeletal muscle ryanodine receptor 1 (RyR1)/calcium release channel can be particularly intolerant of statins. High-resolution structures revealed simvastatin binding sites in the pore region of RyR1. Simvastatin stabilized the open conformation of the pore and activated the RyR1 channel. In a mouse expressing a mutant RyR1-T4709M found in a patient with profound statin intolerance, simvastatin caused muscle weakness associated with leaky RyR1 channels. Cotreatment with a Rycal drug that stabilizes the channel closed state prevented simvastatin-induced muscle weakness. Thus, statin binding to RyR1 can cause SAMS, and patients with RyR1 mutations may represent a high-risk group for statin intolerance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Cellular Biophysics, Clyde and Helen Wu Center for Molecular Cardiology, Vagelos College of Physicians and Surgeons, Columbia University Medical Center, New York, New York, USA.
- Department of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, New York, USA.
Förderung
- NIAMS NIH HHS
- NHLBI NIH HHS
- National Institutes of Health / National Heart, Lung, and Blood Institute
- National Institutes of Health / National Institute of Diabetes, Digestive & Kidney Diseases
- National Institutes of Health / National Institute of Neurological Disorders and Stroke
- National Institutes of Health / National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Weninger, G., Dridi, H., Reiken, S., Yuan, Q., Zhao, N., Groom, L., Leigh, J., Liu, Y., Tchagou, C., Kang, J., Chang, A., Luna-Figueroa, E., Miotto, M. C., Wronska, A., Dirksen, R. T., & Marks, A. R. (2025). Structural basis for simvastatin-induced skeletal muscle weakness associated with type 1 ryanodine receptor T4709M mutation. Journal of Clinical Investigation. https://doi.org/10.1172/jci194490
Vancouver
Weninger G, Dridi H, Reiken S, Yuan Q, Zhao N, Groom L, et al. Structural basis for simvastatin-induced skeletal muscle weakness associated with type 1 ryanodine receptor T4709M mutation. Journal of Clinical Investigation. 2025. doi:10.1172/jci194490
BibTeX
@article{Weninger2025,
author = {Weninger, Gunnar and Dridi, Haikel and Reiken, Steven and Yuan, Qi and Zhao, Nan and Groom, Linda and Leigh, Jennifer and Liu, Yang and Tchagou, Carl and Kang, Jiayi and Chang, Alexander and Luna-Figueroa, Estefania and Miotto, Marco C and Wronska, Anetta and Dirksen, Robert T and Marks, Andrew R},
title = {Structural basis for simvastatin-induced skeletal muscle weakness associated with type 1 ryanodine receptor T4709M mutation},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci194490}
}
EUVIMED